Ondine Biomedical Inc.
OBIMF
$0.14
$0.000.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 31.01% | 45.31% | 67.62% | 81.70% | 101.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.01% | 45.31% | 67.62% | 81.70% | 101.00% |
| Cost of Revenue | 12.18% | 24.64% | 43.39% | 50.40% | 57.34% |
| Gross Profit | 43.56% | 59.47% | 84.85% | 107.63% | 146.54% |
| SG&A Expenses | 23.53% | 15.67% | 10.56% | -11.66% | -30.18% |
| Depreciation & Amortization | -3.51% | -6.44% | -7.53% | -2.50% | 2.12% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.45% | 43.46% | 32.04% | 6.31% | -16.42% |
| Operating Income | -60.41% | -43.28% | -29.15% | -1.75% | 21.55% |
| Income Before Tax | -62.49% | -44.89% | -30.31% | 0.03% | 24.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -62.49% | -44.89% | -30.31% | 0.03% | 24.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.49% | -44.89% | -30.31% | 0.03% | 24.64% |
| EBIT | -60.41% | -43.28% | -29.15% | -1.75% | 21.55% |
| EBITDA | -59.69% | -43.19% | -29.64% | -1.90% | 21.62% |
| EPS Basic | 1.46% | 5.47% | 7.37% | 21.69% | 33.43% |
| Normalized Basic EPS | 3.61% | 7.65% | 9.25% | 21.52% | 31.92% |
| EPS Diluted | 1.46% | 5.47% | 7.37% | 21.69% | 33.43% |
| Normalized Diluted EPS | 3.61% | 7.65% | 9.25% | 21.52% | 31.92% |
| Average Basic Shares Outstanding | 68.94% | 54.95% | 39.31% | 26.37% | 13.27% |
| Average Diluted Shares Outstanding | 68.94% | 54.95% | 39.31% | 26.37% | 13.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |